Biscayne Neurotherapeutics’ platform is based on huperzine A, a highly potent acetylcholinesterase inhibitor (AChE). Huperzine A is a single agent traditional Chinese medicine with a long history of safety that has been widely used to treat CNS ailments. It has demonstrated potential efficacy in multiple models of CNS disorders, including pain and challenging epileptic conditions, such as refractory complex partial seizures (focal seizures) and Dravet syndrome. Biscayne’s BIS-001 is a synthetic form of huperzine A, and is being developed in an extended release formulation named BIS-001 ER. BIS-001 has a number of important advantages compared to native huperzine A and is protected by a strong intellectual property portfolio.
About The Science